NuMat Technologies Closes $12.4M Funding Round to Accelerate Commercialization of Molecularly Engineered Products

By Kevin SlawinApril 26, 2018February 4th, 2021No Comments

Numat Technologies
NuMat Technologies Closes $12.4M Funding Round to Accelerate Commercialization of Molecularly Engineered Products
April 26, 2018

Kevin Slawin

Previous PostPoseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer
Next PostPoseida raises $30.5 million for cancer cell therapy

NuMat Technologies Closes $12.4M Funding Round to Accelerate Commercialization of Molecularly Engineered Products

Kevin Slawin

Previous PostPoseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer

Next PostPoseida raises $30.5 million for cancer cell therapy